Iktos review
A drug-discovery suite linking constrained molecule design to automated synthesis and testing.
Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026
Iktos brings molecule design, retrosynthesis, and laboratory automation into a drug-discovery suite for pharmaceutical, biotech, and academic teams. Makya supports ligand- and structure-based molecular modeling, with target product profile constraints, SAR and ADMET modeling, and multi-parameter optimization. Spaya generates and ranks retrosynthesis routes; its API also provides synthetic-feasibility scoring and route-step estimates. The overall offering is aimed at teams that want to connect computational design with synthesis and biological testing, rather than teams looking only for a standalone modeling tool.
The breadth of the workflow is its central distinction. Iktos describes a process spanning design, synthesis, purification, analysis, and biological testing, supported by robotics and orchestration tools. Custom synthesis constraints can account for suppliers, reactions, and intermediates. For teams with automated laboratory workflows, that link between proposed molecules and testing may be especially relevant. The platform also supports integrations with KNIME, Pipeline Pilot, Jupyter Notebook, and AWS. Teams should assess how those tools fit their existing workflows and whether they need the integrated synthesis and testing capabilities; a group seeking only route generation or molecular modeling may find the broader scope unnecessary.
Iktos offers the platform through a contact-sales model, and prospective customers are directed to request a demo or contact the company. The listed support channel is email. Spaya documentation describes AWS hosting or deployment on a customer's VPC, while the platform is listed as cloud-based; teams evaluating deployment should clarify which arrangement applies to their intended use. Iktos also offers drug-discovery collaborations, but the core product is most suited to mid-market and enterprise organizations with computational and experimental capabilities to connect. Smaller teams or buyers looking for self-serve pricing, or a narrow tool without laboratory automation, may prefer to compare alternatives.
Iktos pros and cons
- Where it wins
- Generates molecules against target product profile constraints
- Combines SAR, ADMET, and multi-parameter compound scoring
- Connects design with automated synthesis and biological testing workflows
- Where it doesn't
- Pricing is available through contact sales
- The listed support channel is email
- The platform's components and workflows may call for specialist drug-discovery teams
Iktos fact sheet, pricing and score →
Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. Bought places stand at the number bought; this page and our disclosure say so. Paying vendors may get a fuller, more detailed review from our editors, and that review can change their score. How we rank.
Last updated · How we research and update